LOGOS GLOBAL MANAGEMENT LP
Q3 2025 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001792126
· CRD 305162
· SEC-registered investment adviser
$1.1B Reported Value Total
LOGOS GLOBAL MANAGEMENT, L.P. reports 6 total accounts under management (AUM). There are 6 discretionary accounts valued at $1,435,498,601, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
7 funds
· $2.3B gross asset value
Hedge Fund: $1.5B · Venture Capital Fund: $749.4M
Source: Form ADV filed 2026-04-22
Reported value
$1.1B
Quarter over quarter
+29.6%
Holdings
53
Top-10 concentration
42.3%
Key People
Form ADV owners & control persons
Arsani Hany William
MANAGING PARTNER / CHIEF INVESTMENT OFFICER
Graham Gordon Walmsley
MANAGING PARTNER / LIMITED PARTNER
Cynthia Louise Goldsmith
CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2025 13F record
Q3 2025 13F filing summary
| Period of report | September 30, 2025 |
|---|---|
| Filed | November 14, 2025 |
| Form | 13F-HR |
| Reported value | $1.1B |
| Positions | 53 |
| Change in reported value | +23.4% |
| New positions | 21 |
| Exited positions | 13 |
| Position turnover | 51.5% |
| Top-10 concentration | 42.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
68 | $2.3B |
|
Q1 2026 13F
Filed May 15, 2026
|
63 | $2.0B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
64 | $1.7B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
53 | $1.1B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
45 | $903.8M |
|
Q1 2025 13F
Filed May 15, 2025
|
39 | $562.5M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
47 | $854.6M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
53 | $926.8M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
51 | $1.2B |
|
Q1 2024 13F
Filed May 15, 2024
|
50 | $1.2B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
47 | $1.1B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
52 | $749.5M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
50 | $735.2M |
|
Q1 2023 13F
Filed May 15, 2023
|
43 | $698.7M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
40 | $853.6M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
38 | $813.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
32 | $545.1M |
|
Q1 2022 13F
Filed May 16, 2022
|
47 | $771.3M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
66 | $969.6M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
57 | $1.4B |
7 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RVMD REVOLUTION MEDICINES INC | $81.7M | 7.33% |
| 2 | IDYA IDEAYA BIOSCIENCES INC | $61.2M | 5.49% |
| 3 | AKRO AKERO THERAPEUTICS INC | $57.0M | 5.11% |
| 4 | ARVN ARVINAS INC | $47.5M | 4.26% |
| 5 | RVMD C REVOLUTION MEDICINES INC | $46.7M | 4.19% |
| 6 | OCUL OCULAR THERAPEUTIX INC | $38.0M | 3.41% |
| 7 | CDTX CIDARA THERAPEUTICS INC | $35.9M | 3.22% |
| 8 | VSTM VERASTEM INC | $35.8M | 3.21% |
| 9 | ABVX ABIVAX SA | $35.2M | 3.16% |
| 10 | ERAS ERASCA INC | $33.0M | 2.96% |
| 11 | MAZE MAZE THERAPEUTICS INC | $31.8M | 2.85% |
| 12 | OLMA OLEMA PHARMACEUTICALS INC | $31.4M | 2.82% |
| 13 | IMCR IMMUNOCORE HLDGS PLC | $30.9M | 2.77% |
| 14 | DYN DYNE THERAPEUTICS INC | $30.4M | 2.72% |
| 15 | IRON DISC MEDICINE INC | $29.7M | 2.67% |
| 16 | DSGN DESIGN THERAPEUTICS INC | $27.5M | 2.47% |
| 17 | JAZZ JAZZ PHARMACEUTICALS PLC | $26.4M | 2.36% |
| 18 | RNA AVIDITY BIOSCIENCES INC | $26.1M | 2.34% |
| 19 | GPCR STRUCTURE THERAPEUTICS INC | $23.8M | 2.13% |
| 20 | JANX JANUX THERAPEUTICS INC | $22.9M | 2.05% |
Values as reported on the Q3 2025 Form 13F. Every position is in the holdings table below.